Protea Biosciences Group Inc (PRGB)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Protea Biosciences Group Inc (PRGB) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011230
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月22日
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Protea Biosciences Group Inc (Protea) is a biotechnology company that develops mass spectometry solutions. The company offers technology for the characterization, identification, and quantitation of biologically-important molecules for research, pharmaceutical development, and diagnostic applications. Its products include protein sample preparation, functionalized pipette tips and plates, gel protein separation and recovery, mass spectrometry standards and amplus HPLC columns. Protea’s services include mass spec imaging services and bioanalytical services. The company’s bioanalytical services include biotherapeutic characterization, biomarker discovery, advanced proteomics and protein and peptide quantitation, among others. It also provides label free imaging, translational, and drug and metabolite distribution. The company serves in the fields of pharmaceutical, clinical, academic and industrial research. Protea is headquartered in Morgantown, West Virginia, the US.

Protea Biosciences Group Inc (PRGB) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Protea Biosciences Group Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Protea Biosciences Group Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Protea Biosciences Group Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Protea Biosciences Group Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Protea Biosciences Group Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Protea Biosciences Group Inc, Medical Equipment, Deal Details 12
Venture Financing 12
Protea Biosciences Raises US$0.28 Million In Venture Financing 12
Protea Biosciences Secures US$1.05 Million In Venture Financing 13
Partnerships 14
Protea Biosciences Enters into Licensing Agreement with Yale University 14
Protea Biosciences Enters into Research Agreement with Vaccine and Immunotherapy Center 15
Protea Biosciences Enters into Agreement with Massachusetts General Hospital 16
Protea Biosciences Extends Partnership with Protein Metrics 17
Protea Biosciences Enters into Agreement with Agilent Technologies 18
Protea Biosciences Enters into Agreement with InSphero for 3D Technologies 19
Protea Biosciences Enters Into Research Agreement With Virginia Commonwealth University For Molecular Imaging Techniques 20
Waters Enters Into Co-Marketing Agreement With Protea Biosciences Group For LASEI DP-1000 21
Equity Offering 22
Protea Biosciences Files Registration Statement to Raise up to USD17.3 Million in Public Offering of Shares 22
Protea Biosciences Group Raises USD0.6 Million in Private Placement 23
Protea Biosciences to Raise Funds through Public Offering of Shares 24
Protea Biosciences Raises USD0.98 Million in Public Offering of Units 25
Protea Biosciences Raises USD2.53 Million in Public Offering of Units 26
Protea Biosciences Group Completes Private Placement Of Shares For US$0.7 Million 27
Protea Biosciences Completes Private Placement Of Shares For US$0.5 Million 28
Debt Offering 29
Protea Biosciences Raises USD0.1 Million in Private Placement of Debentures 29
Protea Biosciences Raises USD1.61 Million in Private Placement of Debentures 30
Protea Biosciences Raises USD2 Million in Private Placement of Debentures 31
Protea Biosciences Group Completes Private Placement Of Debt Securities For US$0.3 Million 32
Asset Transactions 33
Purdue University Acquires LAESI DP-1000 Instrument System from Protea Biosciences 33
Princeton University Acquires LAESI DP-1000 Instrument System from Protea Biosciences 34
United States Department of Agriculture Acquires Laesi DP-1000 from Protea Biosciences 35
Acquisition 36
SRKP 5 Acquires Protea Biosciences In Reverse Takeover Transaction 36
Protea Biosciences Group Inc – Key Competitors 37
Protea Biosciences Group Inc – Key Employees 38
Protea Biosciences Group Inc – Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Financial Announcements 40
Apr 18, 2017: Protea Announces 2016 Year End Results 40
Nov 22, 2016: Protea Announces Third Quarter 2016 Results 41
Aug 16, 2016: Protea Announces Second Quarter 2016 Results 42
May 16, 2016: Protea Announces First Quarter 2016 Results 43
Mar 16, 2016: Protea Announces 2015 Year End Results 44
Corporate Communications 45
Nov 10, 2016: Protea Appoints David Halverson As President 45
Product News 46
Apr 19, 2016: New Potential Lung Cancer Biomarkers Identified 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Protea Biosciences Group Inc, Medical Equipment, Key Facts, 2016 2
Protea Biosciences Group Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Protea Biosciences Group Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Protea Biosciences Group Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Protea Biosciences Group Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Protea Biosciences Group Inc, Deals By Market, 2011 to YTD 2017 9
Protea Biosciences Group Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Protea Biosciences Raises US$0.28 Million In Venture Financing 12
Protea Biosciences Secures US$1.05 Million In Venture Financing 13
Protea Biosciences Enters into Licensing Agreement with Yale University 14
Protea Biosciences Enters into Research Agreement with Vaccine and Immunotherapy Center 15
Protea Biosciences Enters into Agreement with Massachusetts General Hospital 16
Protea Biosciences Extends Partnership with Protein Metrics 17
Protea Biosciences Enters into Agreement with Agilent Technologies 18
Protea Biosciences Enters into Agreement with InSphero for 3D Technologies 19
Protea Biosciences Enters Into Research Agreement With Virginia Commonwealth University For Molecular Imaging Techniques 20
Waters Enters Into Co-Marketing Agreement With Protea Biosciences Group For LASEI DP-1000 21
Protea Biosciences Files Registration Statement to Raise up to USD17.3 Million in Public Offering of Shares 22
Protea Biosciences Group Raises USD0.6 Million in Private Placement 23
Protea Biosciences to Raise Funds through Public Offering of Shares 24
Protea Biosciences Raises USD0.98 Million in Public Offering of Units 25
Protea Biosciences Raises USD2.53 Million in Public Offering of Units 26
Protea Biosciences Group Completes Private Placement Of Shares For US$0.7 Million 27
Protea Biosciences Completes Private Placement Of Shares For US$0.5 Million 28
Protea Biosciences Raises USD0.1 Million in Private Placement of Debentures 29
Protea Biosciences Raises USD1.61 Million in Private Placement of Debentures 30
Protea Biosciences Raises USD2 Million in Private Placement of Debentures 31
Protea Biosciences Group Completes Private Placement Of Debt Securities For US$0.3 Million 32
Purdue University Acquires LAESI DP-1000 Instrument System from Protea Biosciences 33
Princeton University Acquires LAESI DP-1000 Instrument System from Protea Biosciences 34
United States Department of Agriculture Acquires Laesi DP-1000 from Protea Biosciences 35
SRKP 5 Acquires Protea Biosciences In Reverse Takeover Transaction 36
Protea Biosciences Group Inc, Key Competitors 37
Protea Biosciences Group Inc, Key Employees 38
Protea Biosciences Group Inc, Subsidiaries 39

★海外企業調査レポート[Protea Biosciences Group Inc (PRGB)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Polymedco Inc-医療機器分野:企業M&A・提携分析
    Summary Polymedco Inc (Polymedco) is a medical device company that manufactures and markets laboratory instruments, reagents and kits. The company provides FIT testing, ESR testing, chemistry testing instruments, oc-auto fit, oc-lights fit, oc-auto sensor, diana, oc-automicro 80, epi procolon, sedit …
  • Vernalis Plc (VER)-製薬・医療分野:企業M&A・提携分析
    Summary Vernalis plc (Vernalis) is a pharmaceutical company, which focuses at developing novel pharmaceuticals for the treatment of several diseases. The product portfolio of the company comprises frovatriptan for the acute treatment of migraine; Tuzistra XR, which targets the US prescription cough …
  • EnerDel Inc:企業の戦略的SWOT分析
    EnerDel Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • OMEICOS Therapeutics GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary OMEICOS Therapeutics GmbH (OMEICOS) is a biopharmaceutical company that develops small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases. The company utilizes its proprietary technology of the body’s own omega-3 fatty acid metabolic processes to …
  • AG Insurance SA/NV:企業の戦略・SWOT・財務情報
    AG Insurance SA/NV - Strategy, SWOT and Corporate Finance Report Summary AG Insurance SA/NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • The Cheesecake Factory Incorporated:企業の戦略・SWOT・財務情報
    The Cheesecake Factory Incorporated - Strategy, SWOT and Corporate Finance Report Summary The Cheesecake Factory Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Sunesis Pharmaceuticals Inc (SNSS):製薬・医療:M&Aディール及び事業提携情報
    Summary Sunesis Pharmaceuticals Inc (Sunesis), formerly Mosaic Pharmaceuticals, Inc. develops and markets cancer therapeutics for the treatment of solid and hematologic cancers. The company's Vosaroxin is being developed in Phase III clinical trials for the treatment of acute myeloid leukemia (AML). …
  • Scotiabank Private Banking:企業の戦略・SWOT・財務分析
    Scotiabank Private Banking - Strategy, SWOT and Corporate Finance Report Summary Scotiabank Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Marinus Pharmaceuticals Inc (MRNS):企業の財務・戦略的SWOT分析
    Summary Marinus Pharmaceuticals Inc (Marinus) is a clinical stage biopharmaceutical company that manufactures and commercializes therapeutics for the treatment of epilepsy, neuropsychiatric disorders and others diseases. The company’s pipeline product comprise ganaxolone is a CNS-selective GABAA mod …
  • Swissgrid AG:電力:M&Aディール及び事業提携情報
    Summary Swissgrid AG (Swissgrid) is a national grid company that operates, maintains, modernizes and expands the electricity transmission system in Switzerland. It conducts the import and export of electricity to maintain the utilization levels. The company also provides additional services, such as …
  • Unico Sigorta A.S:企業の戦略・SWOT・財務分析
    Unico Sigorta A.S - Strategy, SWOT and Corporate Finance Report Summary Unico Sigorta A.S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Medical Developments International Ltd (MVP):企業の財務・戦略的SWOT分析
    Summary Medical Developments International Ltd (MDI) is a healthcare company that develops, manufactures and markets pain relief and respiratory medicine. The company provides products such as penthrox, asthma and COPD, medical devices and veterinary products. It offers asthma and COPD products whic …
  • TIE Kinetix NV (TIE):企業の財務・戦略的SWOT分析
    TIE Kinetix NV (TIE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Gardner Denver Holdings, Inc. (GDI):企業の財務・戦略的SWOT分析
    Gardner Denver Holdings, Inc. (GDI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Voya Financial Inc:企業の戦略・SWOT・財務分析
    Voya Financial Inc - Strategy, SWOT and Corporate Finance Report Summary Voya Financial Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Shenzhen Neptunus Interlong Bio-Technique Co Ltd (8329):企業の財務・戦略的SWOT分析
    Summary Shenzhen Neptunus Interlong Bio-Technique Co Ltd (Neptunus Interlong) is a provider of cytokine protein therapeutic drugs and preventive biological products. The company provides products such as recombinant human interferon a-2b for injection, recombinant human interleukin-2 for injection a …
  • Osaka Gas Co Ltd (9532):企業の財務・戦略的SWOT分析
    Osaka Gas Co Ltd (9532) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • PPG Industries Inc (PPG):企業の財務・戦略的SWOT分析
    PPG Industries Inc (PPG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • ZTE Corp:企業の戦略・SWOT・財務情報
    ZTE Corp - Strategy, SWOT and Corporate Finance Report Summary ZTE Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Martin Midstream Partners LP (MMLP):企業の財務・戦略的SWOT分析
    Martin Midstream Partners LP (MMLP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆